Robert Barrow Chief Executive Officer and Board Director

Robert Barrow was appointed Chief Executive Officer of Definium Therapeutics (formerly MindMed) in June 2021. Prior to his appointment as CEO, he served as the company's Chief Development Officer. Definium Therapeutics, under its former name MindMed, was initially a venture capital-backed company that went public in March 2020 via a reverse takeover on the Canadian NEO Exchange, and later uplisted to Nasdaq in April 2021.

Brandi Roberts, CPA Chief Financial Officer

Brandi Roberts serves as the Chief Financial Officer of Definium Therapeutics.

Daniel R. Karlin, MD, MA Chief Medical Officer

Daniel R. Karlin is the Chief Medical Officer of Definium Therapeutics. He joined the company in this role in connection with the acquisition of HealthMode, where he had served as CEO.

Stephanie Fagan, MS Chief Corporate Affairs Officer

Stephanie Fagan serves as the Chief Corporate Affairs Officer of Definium Therapeutics.

Mark Sullivan, JD Chief Legal Officer and Corporate Secretary

Mark Sullivan is the Chief Legal Officer and Corporate Secretary of Definium Therapeutics.

The most significant risk is the **risk of clinical trial failure and the uncertainty of regulatory approval** for its drug candidates. Definium Therapeutics is heavily invested in the success of its lead product candidates, DT120 (in Phase 3 for generalized anxiety disorder and major depressive disorder) and DT402 (in Phase 2a for autism spectrum disorder). Despite DT120 receiving FDA Breakthrough Therapy Designation for generalized anxiety disorder, there is no guarantee that these trials will be successful or that the company will secure the necessary regulatory approvals for commercialization. Failure at any stage of clinical development would severely impact the company's future prospects and financial viability.

A second key risk pertains to **regulatory and market acceptance challenges specific to psychedelic-inspired therapeutics**. Definium Therapeutics' approach involves applying scientific rigor to psychedelic-inspired compounds for psychiatric and neurological disorders. This nascent field may encounter unique regulatory hurdles, potentially leading to a longer or more complex approval process compared to traditional pharmaceuticals. Furthermore, even if approved, these novel treatments may face challenges in gaining widespread acceptance from the medical community, overcoming public perception biases, and securing favorable reimbursement policies from insurers.

Finally, the company faces **intellectual property risk**. As a biopharmaceutical company developing novel compounds, Definium Therapeutics' long-term value and competitive position are highly dependent on its ability to obtain, maintain, and defend robust patent protection for its drug candidates and proprietary technologies. Any challenges to its intellectual property, or an inability to secure strong patent portfolios, could undermine its market exclusivity and expose it to competition.

The addressable markets for Mind Medicine (MindMed) Inc.'s main products are as follows:

• MM-120 for Generalized Anxiety Disorder (GAD):
  • The global generalized anxiety disorder treatment market was valued at approximately USD 11.93 billion in 2024 and is predicted to grow to around USD 17.32 billion by 2034.
  • Another estimate places the global market at USD 2.14 billion in 2025, expected to reach USD 5.06 billion by 2035.
  • In 2023, the Generalized Anxiety Disorder market size in the 7 Major Markets (7MM, which includes the United States, EU4, and the United Kingdom, and Japan) reached approximately USD 1,560 million.
  • The United States market for GAD treatment was nearly USD 1,019 million in 2023, representing nearly 65% of the 7MM market.
• MM-120 for Attention Deficit Hyperactivity Disorder (ADHD):
  • The global attention deficit hyperactivity disorder (ADHD) therapeutics market size is estimated at US$ 25.05 billion in 2024 and is forecasted to reach US$ 45.51 billion by 2034.
  • Another report indicates the ADHD market reached USD 9.6 billion in 2023 and is expected to reach USD 13.6 billion by 2034.
  • The ADHD therapeutics market value across eight major markets (the US, the UK, France, Germany, Spain, Italy, Japan, and Canada) was projected to rise from $6.9 billion in 2013 to $9.9 billion by 2020.
  • North America is expected to contribute 40% of the market's growth for ADHD drugs.
• MM-120 for Chronic Pain:
  • The global chronic pain treatment market was valued at USD 78.0 billion in 2024, projected to reach USD 83.4 billion in 2025 and USD 155.2 billion by 2035.
  • Another source valued the global chronic pain treatment market at USD 90.72 billion in 2024 and anticipates it will reach USD 152.42 billion by 2032.
  • North America accounted for the largest market share at 45% in 2024, with over USD 40 billion in chronic pain treatment utilization.
  • North America is forecasted to hold the largest market share at 40.8% in 2025.
• MM-110 for Opioid Withdrawal:
  • The global Opioid Withdrawal Treatment Market is estimated to be valued at USD 1.91 billion in 2026, and projected to reach USD 4.33 billion by 2035.
  • The opioid addiction treatment market will be worth $2.4 billion in eight major world markets by 2033.
  • The market size for opioid withdrawal syndrome in the 7MM (United States, EU4, and the United Kingdom, and Japan) reached approximately USD 1.3 billion in 2022.
  • The United States market for opioid withdrawal treatment was projected at USD 0.61 billion in 2025.
  • North America leads the global opioid withdrawal treatment market with approximately 50% share.
• MM-402 for Autism Spectrum Disorder (ASD):
  • The global autism spectrum disorder treatment market size was estimated at USD 2.16 billion in 2024 and is projected to reach USD 3.95 billion by 2033.
  • Another source indicates the global autism spectrum disorder treatment market was valued at USD 2.35 billion in 2024 and is predicted to increase to approximately USD 4.22 billion by 2034.
  • North America held the largest share of 42.73% of the global market in 2024.
  • The U.S. autism spectrum disorder treatment market size was exhibited at USD 1.00 billion in 2024 and is projected to be worth around USD 1.84 billion by 2034.

Definium Therapeutics, Inc. (DFTX) has several key drivers expected to fuel its future revenue growth over the next 2-3 years, primarily centered around the advancement and potential commercialization of its pipeline of novel therapeutics for brain health disorders.

1. Successful Commercialization of DT120 for Generalized Anxiety Disorder (GAD): The most significant driver is the potential approval and launch of DT120 (formerly MM-120), an orally disintegrating tablet formulation, for Generalized Anxiety Disorder. This lead product candidate is currently in Phase 3 clinical trials, with topline data from the Voyage study anticipated in the first half of 2026 and the Panorama study in the second half of 2026. DT120 has received FDA Breakthrough Therapy Designation for GAD, which could expedite its development and regulatory review process. Analysts project substantial peak U.S. sales for MM120, with potential revenue reaching $2.29 billion by 2031 in the multi-billion-dollar GAD market.
2. Expansion of DT120 into Major Depressive Disorder (MDD): Beyond GAD, DT120 is also being evaluated in Phase 3 trials for Major Depressive Disorder, representing a significant additional market opportunity. A successful outcome in these trials and subsequent regulatory approval would considerably broaden the potential patient population and revenue stream for DT120.
3. Advancement of DT402 for Autism Spectrum Disorder (ASD): The company's pipeline includes DT402 (formerly MM-402), an R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in Phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. Positive clinical trial results and progression to later stages of development could open up another significant revenue pathway in a distinct therapeutic area.
4. Progression of MM-110 for Opioid Withdrawal: The company is also developing MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, which has completed Phase 1 for the treatment of opioid withdrawal. Successful further development and potential commercialization of MM-110 would address another critical area of unmet medical need and contribute to revenue growth.
5. Strategic Preparedness for Commercial Launch: Definium Therapeutics is actively advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. This proactive approach to market entry and infrastructure development is crucial for maximizing revenue generation upon product approval.

Share Repurchases

No significant share repurchases were identified for Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) within the last 3-5 years.

Share Issuance

• The company completed a public offering in November 2025, raising approximately $259 million, with net proceeds of $242.8 million.
• In March 2024, Definium Therapeutics (then Mind Medicine) entered into private placement agreements for 12,500,000 common shares at $6 per share, generating gross proceeds of $75 million.
• Shares outstanding significantly increased from 27 million in fiscal year 2021 to 89 million in fiscal year 2025.

Inbound Investments

• Definium Therapeutics (formerly Mind Medicine) received approximately $259 million through a public offering in November 2025.
• In March 2024, the company secured $75 million in funding from Deep Track Capital, LP, and Commodore Capital through a private placement.
• MindMed has raised funding over nine rounds since November 2019, including post-IPO rounds in March 2021 and August 2023.

Outbound Investments

MindMed acquired HealthMode in October 2020.

Capital Expenditures

• Research and development (R&D) expenditures represent the primary focus of capital deployment, with annual R&D expenses increasing from $34.79 million in FY 2021 to $117.67 million in FY 2025.
• The company invested $31.0 million in research and development during Q3 2025.
• Traditional capital expenditures (property, plant, and equipment) have been reported as minimal or not applicable.